Executive summary of the African-American initiative

MedGenMed Medscape General Medicine

Volumn 9, Issue 1, 2007, Pages

  Yancy, Clyde W ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; PLACEBO; PROPRANOLOL; RAMIPRIL; THIAZIDE DIURETIC AGENT; VALSARTAN;

AFRICAN AMERICAN; ANTIHYPERTENSIVE THERAPY; AWARENESS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG POTENTIATION; ETHNIC DIFFERENCE; EVIDENCE BASED MEDICINE; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MEDICAL EDUCATION; METABOLIC DISORDER; METABOLIC SYNDROME X; MONOTHERAPY; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; RENOVASCULAR HYPERTENSION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; STROKE; UNSPECIFIED SIDE EFFECT; GENETICS; RISK FACTOR; STANDARD;

AFRICAN AMERICANS; CARDIOVASCULAR DISEASES; HUMANS; PRACTICE GUIDELINES; RISK FACTORS;

EID: 33847060426     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. American Heart Association. Heart Disease and Stroke Statistics - 2006 Update. Dallas, Texas: American Heart Association; 2006.
2. Winkleby MA, Kraemer HC, Ahn DK, Varady AN. Ethnic and socioeconomic differences in cardiovascular disease risk factors: Findings for women from the Third National Health and Nutrition Examination Survey, 1988-1994. JAMA. 1998;280:356-362.
3. Watson KE, Fonarow GC. Cardiovascular disease in African Americans. Closing the knowledge, treatment, and outcome gap. Rev Cardiovasc Med. 2004;5:S42-S44.
4. Davis SK, Liu Y, Gibbons GH. Disparities in trends of hospitalization for potentially preventable chronic conditions among African Americans during the 1990s: Implications and benchmarks. Am J Public Health. 2003;93:447-455.
5. Yancy CW, Sica DA. Cardiovascular disease in African Americans. J Clin Hypertens (Greenwich). 2004;6(Suppl 1):54-56.
6. Sica DA. Hypertension and end-organ disease in African Americans: Case presentations. J Clin Hypertens (Greenwich). 2004;6 (Suppl 1):48-53.
7. Durand JB. Heart failure management in African Americans: Meeting the challenge. J Clin Hypertens (Greenwich). 2004;6(Suppl 1):42-47.
8. Yancy CW. Improving outcomes in the post-myocardial infarction setting. J Clin Hypertens (Greenwich). 2004;6(Suppl 1):34-41.
9. Gavin JR, III. Slowing cardiovascular disease progression in African-American patients: Diabetes management. J Clin Hypertens (Greenwich). 2004;6 (Suppl 1):26-33.
10. Saunders E. Managing hypertension in African-American patients. J Clin Hypertens (Greenwich). 2004;6(Suppl 1):19-25.
11. Gibbons GH. Physiology, genetics, and cardiovascular disease: Focus on African Americans. J Clin Hypertens (Greenwich). 2004;6(Suppl 1):11-18.
12. Jamerson KA. The disproportionate impact of hypertensive cardiovascular disease in African Americans: Getting to the heart of the issue. J Clin Hypertens (Greenwich). 2004;6(Suppl 1):4-10.
13. Yancy CW, Gavin JR. Managing cardiovascular disease in African Americans: Emerging strategies for optimizing care. J Clin Hypertens (Greenwich). 2004;6(Suppl 1):2-3.
14. Remme WJ, Riegger G, Hildebrandt P, et al. Do patients necessarily have to start with an angiotensin converting enzyme inhibitor in the treatment of heart failure? Results of the CARMEN (Carvedilol ACE Inhibitor Remodeling Mild CHF EvaluatioN) Study. J Am Coll Cardiol. 2003:41:162A.
15. Bourassa MG, Gurne O, Bangdiwala SI, et al. Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. J Am Coll Cardiol. 1993;22(Suppl A):14A-19A.
16. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
17. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199-206.
18. American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. Dallas, TX: American Heart Association; 2005.
19. MacLeod MJ, McLay J. Drug treatment of hypertension complicating diabetes mellitus. Drugs 1998;56:189-202.
20. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446. Abstract
21. UK Prospective Diabetes Study Group. Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
22. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: Analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail. 1999;5:178-187.
23. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049-2057.
24. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
25. Wright JT, Bakris G, Greene T. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA. 2002;288:2421-2431.
26. Prisant LM, Neutel JM, Ferdinand K, et al. Low-dose combination therapy as first-line hypertension treatment for blacks and nonblacks. J Natl Med Assoc. 1999;91:40-48.
27. Ferdinand KC. Retrospective analysis: Consensus statement of the hypertension in African Americans working group of the International Society on Hypertension in Blacks (ISHIB). Ethn Dis. 2005;15:3-5.
28. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA. 2001;285:2719-2728.
29. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators [published errata appear in N Engl J Med. 2000;342:748 and 2000;342:1376]. N Engl J Med. 2000;342:145-153.
30. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355:253-259.
31. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
32. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
33. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003;163:525-541.
34. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.
35. Man in't Veld AJ, Van den Meiracker AH, Schalekamp MA. Do beta-blockers really increase peripheral vascular resistance? Review of the literature and new observations under basal conditions. Am J Hypertens. 1988;1:91-96.
36. Abraham WT, Tsvetkova T, Lowes BD. Carvedilol improves renal hemodynamics in patients with chronic heart failure. Presented at the 2nd Annual Meeting of the Heart Failure Society of America; September 13-16, 1998; Boca Raton, Florida [abstract 005]. J Card Fail. 1998:4(Suppl 1):307.
37. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7-13.
38. Torp-Pedersen C, Poole-Wilson PA, Swedberg K, et al. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure - COMET. Am Heart J. 2005;149:370-376.
39. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339:489-497.
40. Haywood LJ. Coronary heart disease mortality/morbidity and risk in blacks. I: Clinical manifestations and diagTostic criteria: the experience with the Beta Blocker Heart Attack Trial. Am Heart J. 1984;108:787-793.
41. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110:588-636.
42. Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA. 1988;259:1976-1982.
43. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-1667.
44. Wedel H, DeMets D, Deedwania P, et al. Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HF trial. Am Heart J. 2001;142:502-511.
45. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283:1295-1302.
46. Yancy CW. Heart failure in African Americans: A cardiovascular enigma. J Card Fail. 2000;6:183-186.
47. Abraham WT, Massie BM, Franciosa JA, et al. Tolerability, safety, and efficacy of beta-blockade in black patients with heart failure in the community setting: Insights from a large prospective beta-blocker registry. Presented at the Heart Failure Society of America 7th Annual Scientific Meeting; September 22, 2003; Las Vegas, Nevada [abstract 348]. J Card Fail. 2003;9(suppl 1):S94.
48. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374-381.
49. Torp-Pedersen C, Cleland JG, Metra M, et al. Effect of long-term treatment with carvedilol compared to metoprolol on heart failure morbidity and diabetes in COMET. Presented at the American College of Cardiology (ACC) 53rd Annual Scientific Sessions; March 7-10, 2004, New Orleans, Louisiana. J Am Coll Cardiol. 2004;(suppl A):43.
50. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial. JAMA. 2004;292:2227-2236.
51. Bell DSH, McGill JB, Fonseca V, et al. Demographic analyses of the effects of carvedilol vs. metoprolol in subjects with type 2 diabetes and hypertension in the GEMINI study. Presented at the American Diabetes Association 65th Scientific Sessions; June 10-14, 2005; San Diego, California. Abstract 558-P.
52. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation. 2001;104:2158-2163.
53. Hjalmarson A. Prevention of sudden cardiac death with beta blockers. Clin Cardiol. 1999;22(Suppl 5):V11-V15.
54. McMurray J, Kober L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol. 2005;45:525-530.
55. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335-342.
56. Peterson ED, Shaw LK, DeLong ER, Pryor DB, Califf RM, Mark DB. Racial variation in the use of coronary-revascularization procedures. Are the differences real? Do they matter? N Engl J Med. 1997;336:480-486.